Cargando…

Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency

INTRODUCTION: Standard treatment for patients with primary immunodeficiency (PID) is monthly intravenous immunoglobulin (IVIG), or weekly/biweekly subcutaneous immunoglobulin (SCIG) infusion. We used population pharmacokinetic modeling to predict immunoglobulin G (IgG) exposure following a broad ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidhu, Jagdev, Rojavin, Mikhail, Pfister, Marc, Edelman, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254869/
https://www.ncbi.nlm.nih.gov/pubmed/25118975
http://dx.doi.org/10.1007/s13554-014-0018-0
_version_ 1782347363130540032
author Sidhu, Jagdev
Rojavin, Mikhail
Pfister, Marc
Edelman, Jonathan
author_facet Sidhu, Jagdev
Rojavin, Mikhail
Pfister, Marc
Edelman, Jonathan
author_sort Sidhu, Jagdev
collection PubMed
description INTRODUCTION: Standard treatment for patients with primary immunodeficiency (PID) is monthly intravenous immunoglobulin (IVIG), or weekly/biweekly subcutaneous immunoglobulin (SCIG) infusion. We used population pharmacokinetic modeling to predict immunoglobulin G (IgG) exposure following a broad range of SCIG dosing regimens for initiation and maintenance therapy in patients with PID. METHODS: Simulations of SCIG dosing were performed to predict IgG concentration–time profiles and exposure metrics [steady-state area under the IgG concentration–time curve (AUC), IgG peak concentration (C (max)), and IgG trough concentration (C (min)) ratios] for various infusion regimens. RESULTS: The equivalent of a weekly SCIG maintenance dose administered one, two, three, five, or seven times per week, or biweekly produced overlapping steady-state concentration–time profiles and similar AUC, C (max), and C (min) values [95% confidence interval (CI) for ratios was 0.98–1.03, 0.95–1.09, and 0.92–1.08, respectively]. Administration every 3 or 4 weeks resulted in higher peaks and lower troughs; the 95% CI of the AUC, C (max), and C (min) ratios was 0.97–1.04, 1.07–1.26, and 0.86–0.95, respectively. IgG levels >7 g/L were reached within 1 week using a loading dose regimen in which the weekly maintenance dose was administered five times in the first week of treatment. In patients with very low endogenous IgG levels, administering 1.5 times the weekly maintenance dose five times in the first week of treatment resulted in a similar response. CONCLUSIONS: The same total weekly SCIG dose can be administered at different intervals, from daily to biweekly, with minimal impact on serum IgG levels. Several SCIG loading regimens rapidly achieve adequate serum IgG levels in treatment-naïve patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13554-014-0018-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4254869
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-42548692014-12-05 Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency Sidhu, Jagdev Rojavin, Mikhail Pfister, Marc Edelman, Jonathan Biol Ther Original Research INTRODUCTION: Standard treatment for patients with primary immunodeficiency (PID) is monthly intravenous immunoglobulin (IVIG), or weekly/biweekly subcutaneous immunoglobulin (SCIG) infusion. We used population pharmacokinetic modeling to predict immunoglobulin G (IgG) exposure following a broad range of SCIG dosing regimens for initiation and maintenance therapy in patients with PID. METHODS: Simulations of SCIG dosing were performed to predict IgG concentration–time profiles and exposure metrics [steady-state area under the IgG concentration–time curve (AUC), IgG peak concentration (C (max)), and IgG trough concentration (C (min)) ratios] for various infusion regimens. RESULTS: The equivalent of a weekly SCIG maintenance dose administered one, two, three, five, or seven times per week, or biweekly produced overlapping steady-state concentration–time profiles and similar AUC, C (max), and C (min) values [95% confidence interval (CI) for ratios was 0.98–1.03, 0.95–1.09, and 0.92–1.08, respectively]. Administration every 3 or 4 weeks resulted in higher peaks and lower troughs; the 95% CI of the AUC, C (max), and C (min) ratios was 0.97–1.04, 1.07–1.26, and 0.86–0.95, respectively. IgG levels >7 g/L were reached within 1 week using a loading dose regimen in which the weekly maintenance dose was administered five times in the first week of treatment. In patients with very low endogenous IgG levels, administering 1.5 times the weekly maintenance dose five times in the first week of treatment resulted in a similar response. CONCLUSIONS: The same total weekly SCIG dose can be administered at different intervals, from daily to biweekly, with minimal impact on serum IgG levels. Several SCIG loading regimens rapidly achieve adequate serum IgG levels in treatment-naïve patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13554-014-0018-0) contains supplementary material, which is available to authorized users. Springer Healthcare 2014-08-14 /pmc/articles/PMC4254869/ /pubmed/25118975 http://dx.doi.org/10.1007/s13554-014-0018-0 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Sidhu, Jagdev
Rojavin, Mikhail
Pfister, Marc
Edelman, Jonathan
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
title Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
title_full Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
title_fullStr Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
title_full_unstemmed Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
title_short Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
title_sort enhancing patient flexibility of subcutaneous immunoglobulin g dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254869/
https://www.ncbi.nlm.nih.gov/pubmed/25118975
http://dx.doi.org/10.1007/s13554-014-0018-0
work_keys_str_mv AT sidhujagdev enhancingpatientflexibilityofsubcutaneousimmunoglobulingdosingpharmacokineticoutcomesofvariousmaintenanceandloadingregimensinthetreatmentofprimaryimmunodeficiency
AT rojavinmikhail enhancingpatientflexibilityofsubcutaneousimmunoglobulingdosingpharmacokineticoutcomesofvariousmaintenanceandloadingregimensinthetreatmentofprimaryimmunodeficiency
AT pfistermarc enhancingpatientflexibilityofsubcutaneousimmunoglobulingdosingpharmacokineticoutcomesofvariousmaintenanceandloadingregimensinthetreatmentofprimaryimmunodeficiency
AT edelmanjonathan enhancingpatientflexibilityofsubcutaneousimmunoglobulingdosingpharmacokineticoutcomesofvariousmaintenanceandloadingregimensinthetreatmentofprimaryimmunodeficiency